174 related articles for article (PubMed ID: 32183159)
1. New Selective Progesterone Receptor Modulators and Their Impact on the RANK/RANKL Complex Activity.
Błaszczak-Świątkiewicz K
Molecules; 2020 Mar; 25(6):. PubMed ID: 32183159
[TBL] [Abstract][Full Text] [Related]
2. New Generation of Meso and Antiprogestins (SPRMs) into the Osteoporosis Approach.
Woźniczka M; Błaszczak-Świątkiewicz K
Molecules; 2021 Oct; 26(21):. PubMed ID: 34770897
[TBL] [Abstract][Full Text] [Related]
3. Receptor activator for nuclear factor-κB ligand signaling promotes progesterone-mediated estrogen-induced mammary carcinogenesis.
Boopalan T; Arumugam A; Parada J; Saltzstein E; Lakshmanaswamy R
Cancer Sci; 2015 Jan; 106(1):25-33. PubMed ID: 25412610
[TBL] [Abstract][Full Text] [Related]
4. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.
Gonzalez-Suarez E; Jacob AP; Jones J; Miller R; Roudier-Meyer MP; Erwert R; Pinkas J; Branstetter D; Dougall WC
Nature; 2010 Nov; 468(7320):103-7. PubMed ID: 20881963
[TBL] [Abstract][Full Text] [Related]
5. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
6. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives.
Infante M; Fabi A; Cognetti F; Gorini S; Caprio M; Fabbri A
J Exp Clin Cancer Res; 2019 Jan; 38(1):12. PubMed ID: 30621730
[TBL] [Abstract][Full Text] [Related]
7. Next step in the development of mesoprogestins: the preclinical profile of EC313.
Błaszczak-Świątkiewicz K; Krupa A; Mnich E; Elger W; Oettel M; Nair H; Wierzbicki M; Sieroszewski P; Shaked Z
Front Endocrinol (Lausanne); 2023; 14():1201547. PubMed ID: 37766684
[TBL] [Abstract][Full Text] [Related]
8. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.
Schramek D; Leibbrandt A; Sigl V; Kenner L; Pospisilik JA; Lee HJ; Hanada R; Joshi PA; Aliprantis A; Glimcher L; Pasparakis M; Khokha R; Ormandy CJ; Widschwendter M; Schett G; Penninger JM
Nature; 2010 Nov; 468(7320):98-102. PubMed ID: 20881962
[TBL] [Abstract][Full Text] [Related]
9. RANKL/RANK: from bone loss to the prevention of breast cancer.
Sigl V; Jones LP; Penninger JM
Open Biol; 2016 Nov; 6(11):. PubMed ID: 27881737
[TBL] [Abstract][Full Text] [Related]
10. RANKL/RANK Pathway and Its Inhibitor RANK-Fc in Uterine Leiomyoma Growth.
Ikhena DE; Liu S; Kujawa S; Esencan E; Coon JS; Robins J; Bulun SE; Yin P
J Clin Endocrinol Metab; 2018 May; 103(5):1842-1849. PubMed ID: 29741640
[TBL] [Abstract][Full Text] [Related]
11. RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers.
Nolan E; Vaillant F; Branstetter D; Pal B; Giner G; Whitehead L; Lok SW; Mann GB; ; Rohrbach K; Huang LY; Soriano R; Smyth GK; Dougall WC; Visvader JE; Lindeman GJ
Nat Med; 2016 Aug; 22(8):933-9. PubMed ID: 27322743
[TBL] [Abstract][Full Text] [Related]
12. From the ranks of mammary progesterone mediators, RANKL takes the spotlight.
Fernandez-Valdivia R; Lydon JP
Mol Cell Endocrinol; 2012 Jun; 357(1-2):91-100. PubMed ID: 21964466
[TBL] [Abstract][Full Text] [Related]
13. Progestogens and risk of breast cancer: a link between bone and breast?
González Ricarte M; de Castro Pérez A; Tarín JJ; Cano A
Gynecol Endocrinol; 2016; 32(1):6-8. PubMed ID: 26299383
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
Dougall WC
Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
[TBL] [Abstract][Full Text] [Related]
15. The biology of progesterone receptor in the normal mammary gland and in breast cancer.
Obr AE; Edwards DP
Mol Cell Endocrinol; 2012 Jun; 357(1-2):4-17. PubMed ID: 22193050
[TBL] [Abstract][Full Text] [Related]
16. RANKL inhibition: a promising novel strategy for breast cancer treatment.
González-Suárez E
Clin Transl Oncol; 2011 Apr; 13(4):222-8. PubMed ID: 21493182
[TBL] [Abstract][Full Text] [Related]
17. RANKL/RANK control Brca1 mutation- .
Sigl V; Owusu-Boaitey K; Joshi PA; Kavirayani A; Wirnsberger G; Novatchkova M; Kozieradzki I; Schramek D; Edokobi N; Hersl J; Sampson A; Odai-Afotey A; Lazaro C; Gonzalez-Suarez E; Pujana MA; Cimba F; Heyn H; Vidal E; Cruickshank J; Berman H; Sarao R; Ticevic M; Uribesalgo I; Tortola L; Rao S; Tan Y; Pfeiler G; Lee EY; Bago-Horvath Z; Kenner L; Popper H; Singer C; Khokha R; Jones LP; Penninger JM
Cell Res; 2016 Jul; 26(7):761-74. PubMed ID: 27241552
[TBL] [Abstract][Full Text] [Related]
18. RANKL/RANK - from bone physiology to breast cancer.
Sigl V; Penninger JM
Cytokine Growth Factor Rev; 2014 Apr; 25(2):205-14. PubMed ID: 24486161
[TBL] [Abstract][Full Text] [Related]
19. Progesterone/RANKL is a major regulatory axis in the human breast.
Tanos T; Sflomos G; Echeverria PC; Ayyanan A; Gutierrez M; Delaloye JF; Raffoul W; Fiche M; Dougall W; Schneider P; Yalcin-Ozuysal O; Brisken C
Sci Transl Med; 2013 Apr; 5(182):182ra55. PubMed ID: 23616122
[TBL] [Abstract][Full Text] [Related]
20. Cell-based assay strategy for identification of motif-specific RANK signaling pathway inhibitors.
Chen T; Feng X
Assay Drug Dev Technol; 2006 Aug; 4(4):473-82. PubMed ID: 16945019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
